PCSK9 and Stroke: In the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial, the addition of evolocumab to statin therapy in patients with stable ASCVD reduced LDL‐C by a mean of 59% and significantly reduced the risk of the primary endpoints (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% at 48 weeks.5